Intellia Therapeutics (NASDAQ:NTLA) EVP Sells $84,186.00 in Stock

Intellia Therapeutics, Inc. (NASDAQ:NTLA) EVP Edward Dulac III sold 4,677 shares of the firm’s stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $18.00, for a total value of $84,186.00. Following the completion of the sale, the executive vice president owned 156,286 shares in the company, valued at $2,813,148. The trade was a 2.91% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.

Intellia Therapeutics Stock Performance

Intellia Therapeutics stock opened at $16.84 on Thursday. The company has a 50-day simple moving average of $14.32 and a 200-day simple moving average of $13.25. The firm has a market capitalization of $2.35 billion, a P/E ratio of -4.76 and a beta of 1.77. Intellia Therapeutics, Inc. has a one year low of $7.95 and a one year high of $28.25.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.81) earnings per share for the quarter, beating the consensus estimate of ($0.92) by $0.11. Intellia Therapeutics had a negative net margin of 597.04% and a negative return on equity of 57.47%. The firm had revenue of $15.05 million for the quarter, compared to the consensus estimate of $13.81 million. During the same period last year, the firm posted ($1.10) EPS. As a group, sell-side analysts forecast that Intellia Therapeutics, Inc. will post -3.18 earnings per share for the current year.

Institutional Trading of Intellia Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of NTLA. Farallon Capital Management LLC purchased a new position in shares of Intellia Therapeutics during the 3rd quarter valued at $10,486,000. Wesbanco Bank Inc. purchased a new stake in shares of Intellia Therapeutics during the fourth quarter worth $575,000. Canal Insurance CO acquired a new stake in Intellia Therapeutics during the fourth quarter valued at $899,000. Baker BROS. Advisors LP boosted its position in Intellia Therapeutics by 2.7% during the third quarter. Baker BROS. Advisors LP now owns 2,746,674 shares of the company’s stock valued at $47,435,000 after purchasing an additional 71,000 shares during the last quarter. Finally, Massachusetts Financial Services Co. MA purchased a new position in Intellia Therapeutics in the fourth quarter valued at about $318,000. Institutional investors own 88.77% of the company’s stock.

Wall Street Analyst Weigh In

NTLA has been the subject of several analyst reports. Citigroup reiterated a “market outperform” rating on shares of Intellia Therapeutics in a research report on Monday, June 15th. The Goldman Sachs Group raised their target price on Intellia Therapeutics from $8.00 to $9.00 and gave the company a “sell” rating in a research report on Tuesday, April 28th. Chardan Capital lifted their target price on Intellia Therapeutics from $27.00 to $30.00 and gave the company a “buy” rating in a research note on Monday, April 27th. Sanford C. Bernstein increased their price target on Intellia Therapeutics from $13.00 to $17.00 and gave the stock a “market perform” rating in a research note on Wednesday, May 13th. Finally, New Street Research set a $25.00 price target on Intellia Therapeutics in a report on Monday, June 15th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, ten have assigned a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, Intellia Therapeutics currently has an average rating of “Hold” and an average price target of $20.46.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.